Health Law Alliance (HLA) is proud to share that our very own Diana Yastrovskaya was recently featured for her expertise in a live discussion on Pharmacy Benefit Managers (PBMs) for Pennsylvania TV station, WJAC. In this segment, Diana offered her insights into the complex and often misunderstood role that PBMs play in the healthcare system.
The discussion centered on the impact of PBMs on local pharmacies, the breadth of PBM power, and the challenges this creates for independent businesses. Diana explained how PBMs act as intermediaries between insurers, pharmacies, and drug manufacturers, and how their practices can have significant implications for both patients and providers. She emphasized the importance of transparency in PBM operations and stressed that greater clarity could lead to more affordable and accessible medications for consumers.
Importantly, Diana shared how she works directly with independent pharmacies to help them push back against unfair PBM practices. Through her expertise in healthcare law and regulatory frameworks, she advocates for policies that empower smaller pharmacies to compete on a more level playing field.
Her participation in the WJAC discussion reflects HLA’s ongoing commitment to advancing critical conversations around healthcare law, policy, and practice. By breaking down complex industry dynamics and providing actionable guidance, Diana continues to champion fairness, efficiency, and patient well-being.
Read more about our best PBM Attorney, Diana Yastrovskaya, Esq.
MORE ARTICLES BY CATEGORY
Texas Moves to Rein in Ketamine Therapy—And Other States are Likely Next
The regulatory environment surrounding ketamine therapy is entering a new phase of maturity and enforcement. Recently, the Texas Medical Board published proposed regulations governing ketamine therapy, one of the first comprehensive regulatory frameworks in the country.
Read More >>California Hospice Fraud Crackdown: What it Means for Providers & How to Protect Your Business
California’s hospice fraud crackdown is only the beginning of what CMS and Medi-Cal regulators have claimed will be many more cases brought against hospice facilities and home health agencies. Providers who do not timely respond to a suspension or revocation may waive important rights. Act now to protect your business and reputation from governmental overreach based on data mining and other unreliable sources.
Read More >>New Executive Order Signals Faster Psychedelic Drug Approvals--and Closer DEA Scrutiny
On Saturday, April 18, President Trump signed an executive order designed to accelerate federal drug approvals for psychedelic drugs, a move experts are calling a significant win for patient access. But for ketamine providers and practices offering ketamine-assisted psychotherapy (KAP), increased coordination among regulators means increased scrutiny is inevitable. In this article, we break down what this executive order means for the future of regulatory enforcement.
Read More >>The WISeR Model: A New Era of Prior Authorization and Audit Risks for Wound Care
On January 1, 2026, the Centers for Medicare & Medicaid Services (CMS) officially launched the Wasteful and Inappropriate Service Reduction (WISeR) Model. This initiative is not just another administrative hurdle; it is a technology-driven enforcement overhaul aimed directly at the wound care industry.
Read More >>
